Breaking Away From Betta, Jacobio Raises China Oncology Development Bar
Emerging Company Profile: Founded by former executives of China’s national innovation darling Betta Pharma, Beijing-based Jacobio is focused on novel oncology assets, led by a KRAS inhibitor that's set to begin Phase I and IIa studies in the US and China for solid tumors.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.
In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.